Episode Details

Contact Nancy Lurker

LinkedIn: https://www.linkedin.com/in/nancy-lurker-6603316/

Lisa Ryan: Hey, it's Lisa Ryan. Welcome to the Manufacturers' Network Podcast. I'm excited to introduce you to our guest today Nancy Lurker. Nancy is President and CEO of EyePoint Pharmaceuticals, a specialty company that develops and manufacturers sustained release drug delivery, innovative ophthalmology products to treat debilitating diseases of the eye, leading to blindness.

Ms. Lurker is a healthcare industry veteran and decision-maker who brings more than 30 years of experience with the public, and private startups, including fortune 500 biotech and pharma companies. Nancy, welcome to the show. It's so good to have you here.

Nancy Lurker: Thank you, Lisa. It's great to be here.

Lisa Ryan: Nancy, please share with us your background, particularly in manufacturing, since that's the audience that we have.

Nancy Lurker: Well, I've spent several years in the pharmaceutical industry at big pharma and several small pharma companies. In almost all cases, except for actually two companies I was at, which was on the service side. I've been in a manufacturing company, so I've got a lot of experience, just in terms of how you think about manufacturing drugs, which is not easy.

Lisa Ryan: I understand that you have some pretty cool technology with what you've developed at your company. Why don't you tell us about what you do?

Nancy Lurker: We have some exciting technology. We are an ocular drug delivery company, making products that we will commercialize ourselves. We also do work with partners, though they might, in some cases, come to with drugs they want to put in our drug delivery technology. The reason is that when you're dealing with drugs that go into the eye, it's very complex. If you can think about the eye, it's tiny, and it's a highly complex organ. Our drug delivery technology is minute. We have one's called Duracert, and one is called Verizon. They're very different from each other. I'll focus on Duracert are because that's our main platform.

It's an amazing drug delivery technology that we can release drugs into the eye. You inject into what's called the posterior back, part of the eye. I know, for listeners, they might be like, 'oh my God, injecting the back of the eye. How horrible!' It's not as bad as it sounds. Doctors are very used to it. It's an extremely small, about the size of a tiny piece of hair in terms of diameter, and that gets injected into the eye. We can tailor the release of the drug depending on the drug. Depending on how long we want it to go - anywhere from three years down to one month. Right now, we have one drug on the market that releases out over three years. This drug is no more than three millimeters long - about one millimeter in diameter. It's amazing!

The patient can't see it. You can't see it. It drops to the bottom of the eye, and it just sits there. It releases a tiny microscopic dose, in this case, asteroid, every single day, 365 days a year, for three years.

We also have a very exciting drug in the pipeline that will release a kinase inhibitor over six months. But, again, based on how we pick these timeframes is based on what doctors want and what's best for patients, in some cases to literally what we can do, because, as you can imagine, the pharmacogenetics from a code dynamics of a drug also have to marry up with a drug delivery technology. So there are some limits there in terms of what we can do.

Lisa Ryan: I love having people in manufacturing on the show because of their passion for it, and you are extremely passionate about what you do. We talked about one of the things before the show was getting more women into STEM, getting more women into manufacturing, and being excited about the missio